Efficacy of gemcitabine combined with erlotinib in patients with advanced pancreatic cancer / 中国医学科学院学报
Acta Academiae Medicinae Sinicae
;
(6): 421-423, 2010.
Article
Dans Chinois
| WPRIM
| ID: wpr-322759
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the efficacy,clinical benefits and toxicities of gemcitabine combined with erlotinib for advanced pancreatic cancer.</p><p><b>METHOD</b>Clinical data of 20 patients with advanced pancreatic cancer treated with gemcitabine 1000 mg/m2 on day 1 and day 8 (repeated every 21 days) plus erlotinib 100-150 mg/d at Peking Union Medical College Hospital was reviewed retrospectively.</p><p><b>RESULTS</b>No patient achieved complete remission or partial remission, 11 patients (55%) had stable disease, and 9 patients (45%) experienced disease progression. The disease control rate was 55%, and clinical benefit rate was 30%. The median progression free survival was 4.0 months, and the median overall survival was 8 months. The total incidence of hematologic toxicity was 70%, including 15% of grade 3-4 leucopenia and 5% of grade 3-4 thrombocytopenia. Eleven patients (55%) had rash, which were all grade 1-2. One patient had grade 2 diarrhea and five had grade 1 transaminase elevation. No chemotherapy-related death occurred.</p><p><b>CONCLUSIONS</b>Gemcitabine combined with erlotinib is an effective regimen for pancreatic cancer with good clinical tolerance. The most common adverse events are hematologic toxicities and rash.</p>
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Tumeurs du pancréas
/
Quinazolines
/
Protocoles de polychimiothérapie antinéoplasique
/
Études rétrospectives
/
Études de suivi
/
Résultat thérapeutique
/
Utilisations thérapeutiques
/
Désoxycytidine
/
Traitement médicamenteux
/
Chlorhydrate d'erlotinib
Type d'étude:
Étude observationnelle
/
Étude pronostique
/
Facteurs de risque
Limites du sujet:
Adulte
/
Adulte très âgé
/
Femelle
/
Humains
/
Mâle
langue:
Chinois
Texte intégral:
Acta Academiae Medicinae Sinicae
Année:
2010
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS